You have to scroll through 20+ paragraphs before you get to the lede...
"Enter Mark Klempner. A physician and infectious-disease scientist at the University of Massachusetts, he’s embarked on an experiment that could upend the field of Lyme treatment. Klempner is the lead creator of a first-of-its-kind antibody shot for preventing Lyme infection."
And the most relevant update comes after around 50 paragraphs in the 3rd from last.
"In February, Klempner's phase-one trial kicked off with 60 participants. The goal of the trial is to determine the right dosage so that a person is protected for six to eight months. Lyme PREP will have to be administered annually, but it's a small price to pay in the minds of infectious- disease experts. If my forehead looks flat, it's because I have been banging my head on the wall for 35 years," says Telford. “We need as many tools as possible to prevent Lyme disease."
In just a few years, Lyme PREP could be available for commercial use. Klempner is eyeballing 2024, and maybe even sooner, depending on how the drug performs in clinical trials."